Information date: 7 November 2026 — Under the NMPA registration framework governed by Order 739 and the 2021 Administrative Measures for Medical Device Registration, a foreign manufacturer filing a Class II or Class III device must submit its registration applicant’s business licence, the overseas manufacturing licence or free-sale certificate, and the authorisation letter. These three categories normally require notarisation in the home country plus legalisation by the Chinese embassy or consulate, or an apostille where the Hague Convention applies to that state. Product test reports, clinical evaluation reports and the technical requirements document are submitted as originals in the applicant’s own name. If the document is issued by a foreign public authority such as a free-sale certificate or manufacturing licence, plan for notarisation plus legalisation or apostille and budget four to eight weeks. If the document is an internal authorisation, quality system certificate or statement of non-rejection by the home regulator, check the current NMPA review guidelines for that device category before assuming self-declaration is permitted. Where timelines are tight, sequence legalisation of the free-sale certificate first because it has the longest external lead time.
Verified facts and scope
Under the NMPA registration framework governed by Order 739 and the 2021 Administrative Measures for Medical Device Registration, a foreign manufacturer filing a Class II or Class III device must submit its registration applicant’s business licence, the overseas manufacturing licence or free-sale certificate, and the authorisation letter. These three categories normally require notarisation in the home country plus legalisation by the Chinese embassy or consulate, or an apostille where the Hague Convention applies to that state. Product test reports, clinical evaluation reports and the technical requirements document are submitted as originals in the applicant’s own name.
Scope has to be fixed before the numbers mean anything: Applies to foreign-invested or overseas manufacturers filing initial registration, renewal or change registration for Class II and Class III devices, and to the agent filing on their behalf. Confirm first: the device’s Chinese classification, whether the home country is a Hague Apostille Convention member, whether the certificate of free sale is issued at national or state level, and whether the Chinese agent holds a Class II or Class III Medical Device Business Licence covering the product scope. Anything outside that set is a separate question with its own evidence requirement, and mixing the two is the most common way a workable plan turns into an unusable one.
For a decision on “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead”, keep three layers apart: the published rule or statistic, the company’s own orders and process records, and the assumptions nobody has tested yet. The first layer defines the external conditions, the second proves what is true for this business, and the third is where the risk actually sits. Public material cannot substitute for a contract, a system log, a sample or a live test.
A practical way to test the scope is to ask which parts of “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead” would still be true if the company changed supplier, entity or product line tomorrow. Items that survive that change belong to the rule layer and can be taken from official publications; items that do not survive belong to the operating layer and have to be rebuilt from invoices, warehouse records, customs entries or platform statements. Where Applies to foreign-invested or overseas manufacturers filing initial registration, renewal or change registration for Class II and Class III devices, and to the agent filing on their behalf. Confirm first: the device’s Chinese classification, whether the home country is a Hague Apostille Convention member, whether the certificate of free sale is issued at national or state level, and whether the Chinese agent holds a Class II or Class III Medical Device Business Licence covering the product scope, the two layers are frequently mistaken for each other, and an action plan built on the wrong one either over-complies or misses a deadline it never saw coming.
How the effect reaches operations
Notarisation and legalisation exist to let NMPA verify that the foreign-issued document is authentic and that the signatory has authority. Because NMPA cannot check a foreign company registry directly, it delegates that verification to the notary and then to the Chinese mission abroad. Self-declaration is accepted only where the document’s content is within the applicant’s own knowledge and carries legal liability for false statement under the Regulations on the Supervision and Administration of Medical Devices, so it substitutes for third-party verification, not for the underlying fact.
The most common failure is treating the authorisation letter as a formality and signing it in a name that differs from the business licence, which triggers a rejection and restarts the clock. A second misjudgement is assuming apostille replaces consular legalisation for all countries; it does not where the issuing state is not a party. A third is submitting a self-declaration for the certificate of free sale, which the applicant cannot self-certify because it is issued by a regulator.
Translated into an operating sequence, Notarisation and legalisation exist to let NMPA verify that the foreign-issued document is authentic and that the signatory has authority. Because NMPA cannot check a foreign company registry directly, it delegates that verification to the notary and then to the Chinese mission abroad. Self-declaration is accepted only where the document’s content is within the applicant’s own knowledge and carries legal liability for false statement under the Regulations on the Supervision and Administration of Medical Devices, so it substitutes for third-party verification, not for the underlying fact. That ordering matters: check applicability first, then the transmission step, and only then the size of the gap in cost or timing. When an intermediate step cannot be confirmed, the honest response is to narrow the scope of the conclusion rather than to substitute an industry average for the company’s own figures.
The cost of getting the order wrong is asymmetric. A team that checks applicability too late usually discovers it at the point where the shipment, the filing or the invoice can no longer be changed without penalty, and by then the only remaining lever is price. A team that checks early spends a few hours on questions that turn out to be irrelevant, which is cheap by comparison. On “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead” the practical rule is therefore to spend the first hour on scope and the second on the numbers, never the other way round.
Decision
If the document is issued by a foreign public authority such as a free-sale certificate or manufacturing licence, plan for notarisation plus legalisation or apostille and budget four to eight weeks. If the document is an internal authorisation, quality system certificate or statement of non-rejection by the home regulator, check the current NMPA review guidelines for that device category before assuming self-declaration is permitted. Where timelines are tight, sequence legalisation of the free-sale certificate first because it has the longest external lead time.
The conditions should be written down so the decision can be re-run by someone else: Applies to foreign-invested or overseas manufacturers filing initial registration, renewal or change registration for Class II and Class III devices, and to the agent filing on their behalf. Confirm first: the device’s Chinese classification, whether the home country is a Hague Apostille Convention member, whether the certificate of free sale is issued at national or state level, and whether the Chinese agent holds a Class II or Class III Medical Device Business Licence covering the product scope. When those hold, proceed as described; when one is missing, close the gap first and decide afterwards. This is general regulatory information for planning purposes and does not constitute legal, notarisation or registration advice. Document requirements vary by device class and are updated through NMPA review guidelines; confirm the current checklist with a licensed agent before filing.
Two workstreams usually have to move in parallel. The compliance workstream closes the document side of “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead” — registrations, confirmations, filings — while the commercial workstream protects the delivery date, the pricing already quoted and the customer commitments that were made on the earlier reading of the rules. Running them as one queue is how small documentation gaps become missed shipment dates: the commercial side waits for a certificate that could have been requested a week earlier. If the document is issued by a foreign public authority such as a free-sale certificate or manufacturing licence, plan for notarisation plus legalisation or apostille and budget four to eight weeks. If the document is an internal authorisation, quality system certificate or statement of non-rejection by the home regulator, check the current NMPA review guidelines for that device category before assuming self-declaration is permitted. Where timelines are tight, sequence legalisation of the free-sale certificate first because it has the longest external lead time. Set one owner per workstream and one shared status sheet, and treat a red item on either side as a reason to freeze only the affected order.
Implementation checklist
- Map each required document to issuer: company, notary, or foreign regulator.
- Check Hague apostille status of the issuing state before booking consular legalisation.
- Align the authorisation letter signatory name exactly with the business licence.
- Name one decision owner, one execution owner and one review date.
- Keep the source page, access date, entity and internal evidence.
- On any change, reopen only the affected judgement.
Evidence and review
Start with the smallest test that can change the answer: Map each required document to issuer: company, notary, or foreign regulator. Pick one real entity or one representative case, write down the continue, watch and stop conditions in advance, and record the input version, the owner, the start time and the actual result. The first pass should only look at facts that move the decision; formatting preferences are not risk.
The second pass is completed by “Check Hague apostille status of the issuing state before booking consular legalisation”, and someone who did not prepare the file should spot-check one piece of critical evidence. The most common failure is treating the authorisation letter as a formality and signing it in a name that differs from the business licence, which triggers a rejection and restarts the clock. A second misjudgement is assuming apostille replaces consular legalisation for all countries; it does not where the issuing state is not a party. A third is submitting a self-declaration for the certificate of free sale, which the applicant cannot self-certify because it is issued by a regulator. A single small deviation can be corrected in place; a repeated deviation, or one that touches a statutory duty or changes the economics, is what justifies pausing the affected part.
After “Align the authorisation letter signatory name exactly with the business licence”, compare the actual result with the baseline rather than with the impression of the team. If the document is issued by a foreign public authority such as a free-sale certificate or manufacturing licence, plan for notarisation plus legalisation or apostille and budget four to eight weeks. If the document is an internal authorisation, quality system certificate or statement of non-rejection by the home regulator, check the current NMPA review guidelines for that device category before assuming self-declaration is permitted. Where timelines are tight, sequence legalisation of the free-sale certificate first because it has the longest external lead time. When the arrangement is extended to more products, customers or processes, keep the same success test and one complete record per batch. If later information changes, update only the affected fields.
One last discipline keeps the file usable next quarter: write the closing note as if a colleague who has never spoken to the supplier has to act on it. That note states what was verified, on which date, against which source, and what remains open — on “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead” it also states which of the three actions was actually finished and which was only scheduled. Teams that skip the closing note re-litigate the same question every month, and each round costs more than the documentation would have. This is general regulatory information for planning purposes and does not constitute legal, notarisation or registration advice. Document requirements vary by device class and are updated through NMPA review guidelines; confirm the current checklist with a licensed agent before filing.
Limits of the conclusion
This is general regulatory information for planning purposes and does not constitute legal, notarisation or registration advice. Document requirements vary by device class and are updated through NMPA review guidelines; confirm the current checklist with a licensed agent before filing.
The limits are structural rather than cautious wording. Public sources describe rules and market conditions; they do not observe “Medical Device Registration in China: Which Documents a Foreign Manufacturer Must Have Notarised and Legalised — and Where NMPA Accepts a Self-Declaration Instead” inside a specific company. Where the analysis quotes a second-hand interpretation, the original release has to remain reachable, and a figure that cannot be traced back does not enter the decision table. Where the point depends on Applies to foreign-invested or overseas manufacturers filing initial registration, renewal or change registration for Class II and Class III devices, and to the agent filing on their behalf. Confirm first: the device’s Chinese classification, whether the home country is a Hague Apostille Convention member, whether the certificate of free sale is issued at national or state level, and whether the Chinese agent holds a Class II or Class III Medical Device Business Licence covering the product scope, the conclusion is only as current as the last check of those conditions.
